West Virginia Code of State Rules › Agency 11 - Medicine › Title 11 - LEGISLATIVE RULE WEST VIRGINIA BOARD OF MEDICINE › Series 11-06 - Continuing Education for Physicians and Podiatric Physicians › Section 11-6-2 - Definitions

Current through Register Vol. XLI, No. 28, July 12, 2024
Definitions set forth in 11 CSR 1A are hereby incorporated by
				  reference.
2.1. "ABMS" means American
				Board of Medical Specialties.
2.2.
				"Board" means the West Virginia Board of Medicine.
2.3. "Chronic pain" means pain that has
				persisted after reasonable medical efforts have been made to relieve the pain
				or cure its cause and that has continued, either continuously or episodically,
				for longer than three continuous months. For purposes of this rule, "chronic
				pain" does not include pain associated with a terminal condition or illness or
				with a progressive disease that, in the normal course of progression, may
				reasonably be expected to result in a terminal condition or illness.
2.4. "Controlled substances" means drugs that
				are classified by federal or state law in Schedules I, II, III, IV or V, as
				defined in W. Va. Code §
									60A-2-204 through 212.
2.5. "Licensee" means a physician or
				podiatric physician licensed pursuant to the provisions of W. Va. Code §
				30 -3-1 et seq. and the provisions of 11 CSR 1A.
2.6. "Maintenance of certification" means an
				ongoing process of education and assessment for the twenty four member boards
				of the ABMS board certified physicians to improve practice performance in six
				core competencies: professionalism, patient care and professional skills,
				medical knowledge, practice based learning and improvement, interpersonal and
				communication skills, and systems based practice.
2.7. "Opioid" means controlled substance
				medications which are natural and semi-synthetic derivatives of the opium
				poppy, as well as similar synthetic compounds that have analgesic or pain
				relieving properties because of their effects in the central nervous system.
				Opioids include, but are not limited to, codeine, morphine, hydromorphone,
				hydrocodone, oxycodone, methadone, and fentanyl.
2.8. "Reactivation" means re-licensure of an
				eligible former licensee who has not held a license issued by the Board for
				more than one year immediately preceding the request for
				reactivation.
2.9. "Reinstatement"
				means re-licensure of an eligible former licensee whose license automatically
				expired or was subject to a non-disciplinary voluntary surrender less than one
				year prior to the request for reinstatement.
2.10. "Renewal applicant" means a licensee
				who is seeking to renew a license issued by the Board.
2.11. "Reporting period" means the two-year
				period preceding the renewal deadline for a license issued by the Board.
				Continuing education satisfactory to the Board must be obtained in each
				reporting period.
2.12. "Risk
				Assessment and Responsible Prescribing of Controlled Substances" means drug
				diversion training, best-practice prescribing of controlled substances
				training, and training on prescribing and administering an opioid antagonist
				which includes all of the following components:
2.12.1. Risk Assessment and responding to
				drug diversion and drug seeking behavior including:
2.12.1.a. Tools for conducting routine
				patient assessments for risk factors associated with drug diversion, misuse or
				abuse and identification of substance use disorder treatment referral
				resources;
2.12.1.b. West Virginia
				statistics on prescription drug abuse and resulting deaths;
2.12.1.c. Identification of diversion and
				drug seeking tactics and behaviors;
2.12.1.d. Best practices for assessing,
				treating and referring patients suspected of drug seeking behavior, diversion
				or substance use disorder;
2.12.1.e. Introduction to Medication for
				Opioid Use Disorder (MOUD) and training on the effectiveness of MOUD treatment
				including the use of full opioid agonist, partial opioid agonist, and opioid
				antagonists; and
2.12.1.f. Training
				on the impacts of stigma on treatment effectiveness including the concept of
				addiction as a chronic disease.